Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.30
Bid: 0.00
Ask: 1.34
Change: 0.00 (0.00%)
Spread: 0.04 (3.077%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.30
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

25 Jun 2020 18:08

RNS Number : 1441R
RTW Venture Fund Limited
25 June 2020
 

25 June 2020

RTW VENTURE FUND LIMITED

 (the "Company")

 

Results of the Annual General Meeting ("AGM")

 

The Company is pleased to announce that, at the first AGM held at 14.00 BST today, 25 June 2020, each of the Resolutions were duly passed without amendment.

 

The details of each resolution are as follows:

 

ORDINARY RESOLUTIONS

 

Resolution 1

IT WAS RESOLVED to receive and consider the Audited Financial Statements, the Directors' report, and the auditor's report for the financial year ended 31 December 2019.

 

For (including discretionary)

83,541,534 votes

Against

0 votes

Withheld

0 votes

Resolution 2

IT WAS RESOLVED to approve the Directors' remuneration for the financial year ended 31 December 2019 as provided in the Directors' report.

 

For (including discretionary)

83,467,433 votes

Against

74,101 votes

Withheld

0 votes

Resolution 3¹

IT WAS RESOLVED to elect William Simpson as a Director of the Company.

 

For (including discretionary)

83,467,433 votes

Against

0 votes

Withheld

74,101 votes

 

Resolution 4¹

IT WAS RESOLVED to elect Paul Le Page as a Director of the Company.

 

For (including discretionary)

83,467,433 votes

Against

0 votes

Withheld

74,101 votes

 

Resolution 5¹

IT WAS RESOLVED to elect Bill Scott as a Director of the Company.

 

For (including discretionary)

83,467,433 votes

Against

0 votes

Withheld

74,101 votes

 

 

 

Resolution 6¹

IT WAS RESOLVED to elect Stephanie Sirota as a Director of the Company.

 

For (including discretionary)

83,541,534 votes

Against

0 votes

Withheld

0 votes

 

Resolution 7

IT WAS RESOLVED to re-appoint KPMG Channel Islands Limited and KPMG LLP as Auditors of the Company.

 

For (including discretionary)

83,541,534 votes

Against

0 votes

Withheld

0 votes

 

Resolution 8

IT WAS RESOLVED to authorise the Board of Directors to determine the remuneration of the Auditors.

 

For (including discretionary)

83,541,534 votes

Against

0 votes

Withheld

0 votes

 

Details of those resolutions passed, which were not ordinary business of the AGM, follow:-

 

Resolution

Votes For (including discretionary)

Votes Against

Votes Withheld*

9 - Special

83,541,534 votes

0 votes

0 votes

 

*A vote withheld is not a vote in law and is therefore not counted towards the proportion of votes "for" or "against" the Resolution.

 

Resolution 9

That the Company be and is hereby authorised, in accordance with section 315 of the Companies (Guernsey) Law, 2008, as amended (the "Companies Law"), subject to the Listing Rules made by the United Kingdom Financial Conduct Authority and all other applicable legislation and regulations, to make market acquisitions (within the meaning of section 316 of the Companies Law) of its own Ordinary Shares (as defined in the Company's Articles) which may be cancelled or held as treasury shares, provided that:

i. the maximum number of Ordinary Shares authorised to be purchased under this authority shall be 26,650,546 Ordinary Shares (being 14.99 per cent. of the Ordinary Shares in issue as at the Latest Practicable Date, excluding any treasury shares);

ii. the minimum price (exclusive of expenses) which may be paid for an Ordinary Share is US$0.01;

iii. the maximum price (exclusive of expenses) which may be paid for an Ordinary Share shall be not more than an amount equal to the higher of (a) 5 per cent. above the average mid-market value of the Ordinary Shares on the regulated market where the repurchase is carried out for the five Business Days (as defined in the Company's Articles) prior to the day the purchase is made and (b) the higher of (i) the price of the last independent trade and (ii) the highest current independent bid price, in each case on the regulated market where the purchase is carried out; and

such authority to expire on the date which is 15 months from the date of passing of this resolution or, if earlier, at the end of the Annual General Meeting of the Company to be held in 2021 (unless previously renewed, revoked or varied by the Company by special resolution), save that the Company may make a contract to acquire Ordinary Shares under this authority before its expiry which will or may be executed wholly or partly after its expiration and the Company may make an acquisition of Ordinary Shares pursuant to such a contract.

 

Resolution 10

Resolution 10 had been withdrawn with the unanimous consent of the AGM.

 

Responses to investor's questions will be posted on the Company's website after the AGM.

 

¹ The Company notes that the voting rights adjustments under Article 23 were used in respect of resolutions 3, 4, 5 and 6, but this did not affect the outcome of the shareholder vote.

 

For further information

 

RTW Investments, LP +1 (646) 343 9280Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Business Development Associate

 

Ocorian (Company Secretary) +44 (0)1481 742 642Kevin Smith

 

J.P. Morgan Cazenove +44 (0)20 7742 4000

William Simmonds

Oliver Kenyon

James Bouverat (Sales)

 

Barclays +44 (0)20 7623 2323

Tom Swerling

Andrew Tusa

Alwyn Clarke

Ryan McCarthy

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGSEMFWIESSESM
Date   Source Headline
19th Oct 20207:00 amRNSQuarterly Update
16th Oct 20205:19 pmRNSIssue of Equity
14th Oct 20202:31 pmRNSAnnouncement of Share Issuance
14th Oct 20207:00 amRNSNet Asset Value(s)
5th Oct 20207:00 amRNSC4 Therapeutics Prices $182 Million IPO
2nd Oct 20207:00 amRNSPulmonx Prices $190 Million IPO
28th Sep 20204:13 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSInterim Report for the period ended 30 June 2020
21st Sep 20207:00 amRNSAthira Pharma Prices $204.0 Million IPO
15th Sep 20207:00 amRNSNet Asset Value(s)
14th Sep 20201:00 pmRNSSeries B Financing Round in NiKang Therapeutics
2nd Sep 20207:00 amRNSNotice of Interim Report
1st Sep 20207:00 amRNSTotal Voting Rights
17th Aug 20205:16 pmRNSIssue of Equity
14th Aug 20202:01 pmRNSAnnouncement of Share Issuance
14th Aug 20207:00 amRNSNet Asset Value(s)
12th Aug 20207:00 amRNSPortfolio Company Update
3rd Aug 20207:00 amRNSTotal Voting Rights
28th Jul 20206:25 pmRNSHolding(s) in Company
27th Jul 20207:00 amRNSiTeos Therapeutics Prices $201 Million IPO
23rd Jul 202012:00 pmRNSNew Investment in Milestone Pharmaceuticals
22nd Jul 20201:00 pmRNSSeries D Financing in Encoded Therapeutics
21st Jul 20207:00 amRNSQuarterly Update
17th Jul 202011:44 amRNSIssue of Equity - Replacement Announcement
17th Jul 20207:00 amRNSIssue of Equity
16th Jul 20206:08 pmRNSAnnouncement of further Share Issuance
16th Jul 20207:00 amRNSIssue of Equity
15th Jul 20207:00 amRNSNet Asset Value(s)
25th Jun 20206:08 pmRNSResult of AGM
22nd Jun 20201:59 pmRNSAGM Statement
16th Jun 20201:15 pmRNSSeries B Financing in C4 Therapeutics
16th Jun 20207:00 amRNSUpdate on Avidity Biosciences IPO
12th Jun 20209:33 amRNSAvidity Biosciences Prices $259.2 Million IPO
12th Jun 20207:00 amRNSNet Asset Value(s)
4th Jun 202012:30 pmRNSSeries B Financing in Athira Pharma
1st Jun 20207:00 amRNSTotal Voting Rights
21st May 20204:00 pmRNSNotice of AGM
19th May 20205:40 pmRNSIssue of Equity
18th May 20207:00 amRNSAnnouncement of Share Issuance
14th May 20207:00 amRNSNet Asset Value(s)
1st May 20207:00 amRNSTotal Voting Rights
28th Apr 20204:36 pmRNSDirector/PDMR Shareholding
28th Apr 20204:29 pmRNSDirector/PDMR Shareholding
27th Apr 20206:27 pmRNSIssue of Equity
27th Apr 202011:40 amRNSIssue of Equity
27th Apr 20207:00 amRNSAnnouncement of further Share Issuance
24th Apr 20206:27 pmRNSIssue of Equity
23rd Apr 20207:00 amRNSAnnouncement of Share Issuance
22nd Apr 20207:01 amRNSPerformance Allocation Share Distribution Deferral
22nd Apr 20207:00 amRNSAnnual Report and Audited Financial Statements

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.